TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39543521
Drug: Hydrocortisone treatment
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone treatment
Study: 34032717
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg and Acupressure
Study: 32535600
Drug: HBO +
Normalized name: Hib (HbOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO + pharmacological treatment (HBO+P)
Study: 38433074
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (Control)
Study: 33861329
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (n = 93); 12 weekly 90-minute group sessions.
Study: 32207718
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of xeomin and baclofen (10 mg 3 times a day)
Study: 32694494
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (multidisciplinary rehabilitation)
Study: 32885846
Drug: Biologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapy
Study: 36469441
Drug: Bioencapsulated (BEC)
Normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bioencapsulated (BEC) administration of terbinafine (30 mg/kg)
Study: 35841363
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and apremilast combination therapy (Group A)
Study: 35841363
Drug: Methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate monotherapy (Group B)
Study: 33361337
Drug: Doublet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet therapy (placebo + dabrafenib 150 mg orally twice daily + trametinib 2 mg orally once daily)
Study: 35002810
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group (n = 26)
Study: 37102010
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT)
Study: 34815708
Drug: Galcanezumab 240
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab 240 mg
Study: 39583953
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy
Study: 33307277
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids and long-acting beta-agonists (control group)
Study: 34767030
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) injection
Study: 38499358
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen
Study: 35988289
Drug: Continuous blood
Normalized name: Dexcom G6 Receiver Continuous Blood-Glucose M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous blood purification treatment (hemofiltration without heparin followed by hemoadsorption)
Study: 32413530
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules
Study: 35306524
Drug: Opioid administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid administration
Study: 36075246
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg monthly
Study: 34712981
Drug: Bone Marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone Marrow Aspirate (BMA) injection
Study: 35906640
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (50 mg per day for 8 weeks)
Study: 33352008
Drug: PF-06823859 (MAD)
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06823859 (MAD) 100 or 300 mg
Study: 33352008
Drug: PF-06823859 (MAD)
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06823859 (MAD) 600 mg
Study: 38310875
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg/day
Study: 34488856
Drug: Pain neuroscience
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain neuroscience education + craniocervical manual therapy and exercises
Study: 34314737
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of public health measures
Study: 37437694
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment
Study: 35753838
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of EV71 vaccine and MR vaccine
Study: 32926286
Drug: 15N-labeled urea
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15N-labeled urea (5% 15N atom excess) at 60 mg N kg-1 soil with 50 mg Ni kg-1 soil
Study: 34231274
Drug: Training on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training on treatment adherence
Study: 38234165
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol
Study: 33545336
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide (BPO) treatment
Study: 38235411
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs)
Study: 32886337
Drug: Tretinoin 0.05%
Normalized name: TRETINOIN 0.05% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.05% lotion
Study: 35561538
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral CBD
Study: 39722592
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT)
Study: 35465692
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) plus rescue medication (Group A)
Study: 35838363
Drug: rhMG53 protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhMG53 protein (2 mg/kg, intravenous)
Study: 32169111
Drug: Active stimulation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active stimulation plus treatment as usual (TAU)
Study: 33615630
Drug: Prucalopride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride (2 mg)
Study: 33947442
Drug: Continuous erector
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous erector spinae plane block plus intravenous patient‐controlled analgesia with piritramide
Study: 38369528
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (NSS)
Study: 33944698
Drug: Exergaming using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exergaming using the Playpulse platform for a minimum of 45 minutes twice weekly for eight weeks
Study: 34269974
Drug: Sodium iron
Normalized name: Sodium iron EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium iron EDTA (NaFeEDTA) salt-enriched fish powder (250 mg/100 g)
Study: 37830344
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin
Study: 32662827
Drug: MB with
Normalized name: Ionosol-MB
Approvals — FDA: no, EMA: no, PMDA: no
Description: MB with oral irrigation (Waterpik [WP], experimental)
Study: 35940873
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose intravenous paracetamol (10 mg/kg/dose 6 hourly for 72 hours)
Study: 33263237
Drug: Stainless steel
Normalized name: stainless steel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stainless steel wire fixation and BM injection at the fracture line
Study: 33263237
Drug: Plate fixation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plate fixation and BM injection at the fracture line
Study: 33263237
Drug: Stainless steel
Normalized name: stainless steel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stainless steel bone wire fixation and placebo saline injection at the fracture line
Study: 36070920
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) using cilostazol
Study: 37301768
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive treatment
Study: 35450161
Drug: Vigorous walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigorous walking thrice weekly (VIG × 3/week)
Study: 36030400
Drug: Standard-dose quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose quadrivalent inactivated vaccine administered in the outpatient setting 30 days after randomization
Study: 33459175
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT)
Study: 32212483
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (100 mg, tid) for 3 months (Control)
Study: 37148183
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia (CBT-I)
Study: 34916467
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg rifampin
Study: 37166257
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg/kg
Study: 34704709
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% plus 100 µg dexmedetomidine (1 mL)
Study: 34021607
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg biperiden
Study: 32513308
Drug: anti-SARS-CoV-2 human
Normalized name: ANTI-SARS-COV-2 HUMAN IMMUNOGLOBULIN INTRAVENOUS (TC BOVINE-DERIVED),
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-SARS-CoV-2 human convalescent plasma (200 - 250 mL)
Study: 39669005
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention
Study: 39746515
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS)
Study: 33120808
Drug: Ramelteon (Rozerem)
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon (Rozerem) administered 7 days prior and 7 days post-surgery
Study: 33625666
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment only (Control)
Study: 32798723
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (10 mL) added to 1000 mL saline solution
Study: 32640940
Drug: Goal-Directed Hemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-Directed Hemodynamic Therapy (GDHT)
Study: 33757688
Drug: Botulinum toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin-A (BTX-A) injection into masticatory muscles (masseter and temporalis) 2 weeks prior to surgery
Study: 33757688
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection into masticatory muscles (masseter and temporalis) 2 weeks prior to surgery
Study: 34894328
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy
Study: 34360494
Drug: Oxytocin administration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administration to induce or stimulate labour
Study: 38754891
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment
Study: 35182213
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 40 ml of 0.9% normal saline
Study: 32150492
Drug: Epinephrine HFA
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine HFA MDI at doses above 125 μg
Study: 36259487
Drug: Ultrasound-guided platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided platelet-rich plasma (PRP) injection combined with drugs
Study: 36259487
Drug: Ultrasound-guided PRP
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided PRP injection combined with drugs
Study: 32021411
Drug: Meloxicam IV
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam IV 30 mg
Study: 34480579
Drug: Suvorexant 150
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suvorexant 150 mg
Study: 32081787
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell receptor (TCR) repertoire analysis in patients with steroid nonresponsive aGVHD
Study: 32074767
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist
Study: 34922258
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal cannula (HFNC) at 40 L/min
Study: 35701011
Drug: Risankizumab (RZB)
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab (RZB) 150 mg
Study: 38434770
Drug: Crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 250 mg twice daily
Study: 34882500
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg once daily bupropion
Study: 35642832
Drug: Fibrinogen administration
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen administration
Study: 33849683
Drug: Amphetamine 10
Normalized name: amphetamine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine 10 mg
Study: 35256150
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric derisomaltose 1000 mg and darbepoetin 200 μg subcutaneously
Study: 35527666
Drug: Step-up medium
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up medium dose of ICS
Study: 35576279
Drug: Lipid-based nutritional
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutritional supplement (LNS) (535 kcal)
Study: 32747522
Drug: Fremanezumab quarterly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8)
Study: 39327857
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg/day
Study: 33605002
Drug: Intralesional platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional platelet rich plasma (PRP) injection
Study: 33605002
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide (TAC) injection
Study: 38215286
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: 32501897
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for Lebers Congenital Amaurosis
Study: 35122766
Drug: Clinically adjusted
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically adjusted (CA) maintenance therapy
Study: 33762031
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficient (25(OH)D < 30 ng/mL)
Study: 38609994
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy (CT)
Study: 33211152
Drug: Lower dosage
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dosage of oral spermidine supplementation
Study: 32997098
Drug: Low-dose rivaroxaban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rivaroxaban and aspirin
Study: 36121246
Drug: Pulmonary artery
Normalized name: Pulmonary artery blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary artery denervation (PADN) plus a phosphodiesterase‐5 inhibitor
Study: 36121246
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure plus a phosphodiesterase‐5 inhibitor
Study: 37105885
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion
Study: 32459423
Drug: Elagolix plus
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix plus add-back therapy
Study: 39439530
Drug: Rivaroxaban plus
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban plus aspirin
Study: 36275695
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (CCP) with standard treatment
Study: 34228889
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy (ST) discontinued
Study: 32838476
Drug: Outpatient therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient therapy (higher, rapid class)
Study: 34819017
Drug: Quarterly fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Quarterly fremanezumab (675 mg)
Study: 35243870
Drug: Antiplatelet drugs
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet drugs
Study: 33683087
Drug: Topical imiquimod
Normalized name: imiquimod Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod 5% cream
Study: 34917633
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (MP) 0.5 mg/kg, two times daily for 5 days
Study: 33673371
Drug: Intravenous Ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Ferric Carboxy-Maltose (FCM) 1000 mg at baseline
Study: 32374030
Drug: Single-component tablets
Normalized name: 1,3-beta-glucan synthase component FKS1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-component tablets of macitentan (10 mg) and tadalafil (40 mg)
Study: 32764775
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy
Study: 35640529
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg oral THC
Study: 34261530
Drug: Sham intradermal
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham intradermal acupuncture (sham IA) treatment
Study: 35560470
Drug: Dietary nitrate
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary nitrate supplements (140 ml of beetroot juice; 800 mg nitrate/day)
Study: 37652258
Drug: Tanezumab 5
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 5 mg
Study: 36789481
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch
Study: 36224090
Drug: Traditional Oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Oral Hygiene Instruction (OHI)
Study: 39009776
Drug: Beta-blockers
Normalized name: BETA-BLOCKERS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers
Study: 32121000
Drug: Hb threshold
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hb threshold <12.35 g/dL
Study: 32363493
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg every 2 weeks (Q2W)